GASTRIC ADENOCARCINOMA
Clinical trials for GASTRIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis study tested a combination of two drugs, TAS 102 and ramucirumab, in 23 people with advanced stomach or gastroesophageal junction cancer that had stopped responding to prior treatments. The goal was to see if the combination was safe and could help patients live longer. The …
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 12:10 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called TPST-1495, alone or with another drug (pembrolizumab), in 89 people with advanced solid tumors (like colorectal, lung, or head and neck cancer) that had stopped responding to standard treatments. The main goal was to find the safest…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
Triple-Drug cocktail shows promise for Hard-to-Treat stomach cancers
Disease control CompletedThis study tested a combination of three drugs—regorafenib, nivolumab, and chemotherapy—in 30 people with advanced or recurrent stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery. The goal was to see if the combination was safe and could…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated May 26, 2026 12:05 UTC
-
New combo therapy shows promise in stomach cancer battle
Disease control CompletedThis study tested whether adding the drug AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. The trial involved 610 adults and compared AK104 plus chemo to a placebo plus chemo. The main goal was to see if the combin…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated May 26, 2026 12:03 UTC
-
New hope for stomach cancer patients with low HER2 levels?
Disease control CompletedThis study tested a combination of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with advanced HER2-low stomach or gastroesophageal junction cancer who had not received prior treatment. The goal was to find th…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New cancer drug SGN-B6A tested for safety in chinese patients
Symptom relief CompletedThis early-stage study tested a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, or stomach cancers). The main goal was to check for side effects and see how the body processes the drug. It was not designed to measure if t…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Symptom relief
Last updated May 26, 2026 12:06 UTC
-
Which stomach surgery is better for advanced cancer? new study weighs in
Knowledge-focused CompletedThis study looked back at 96 patients with advanced stomach cancer who had either partial or total stomach removal. Researchers compared survival rates and recovery to see which surgery might be better. The goal is to help doctors and patients choose the right operation.
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: NA • Sponsor: National Taiwan University Hospital • Aim: Knowledge-focused
Last updated May 26, 2026 12:00 UTC
-
Study reveals why some wait too long for cancer care
Knowledge-focused CompletedThis study looked at 258 adults with untreated oeso-gastric cancer to understand why some wait longer to see a doctor after noticing symptoms. Researchers examined social, economic, and personal factors that may cause delays. The goal is to help find ways to encourage earlier dia…
Matched conditions: GASTRIC ADENOCARCINOMA
Phase: NA • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated May 13, 2026 16:02 UTC